Indivior shares plunge after US move and profit warning July 9, 2024 Indivior lowered its annual adjusted operating profit forecast and shares in the company plunged.
GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines July 3, 2024 GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise them.
Astrazeneca drug gets US approval for use on endometrial cancer June 17, 2024 Astrazeneca's Imfinzi drug has gained FDA approval for use on patients with primary or advanced endometrial cancer.
Hikma bolsters US injectables offering with purchase of Danish competitor June 17, 2024 Hikma Pharmaceuticals has bolstered its US injectables capabilities with the purchase of several divisions of Danish competitor Xellia Pharmaceuticals.
Tables turned? Cambridge pharma firm launches hostile bid for New York-listed peer June 7, 2024 Vanda Pharmaceuticals, based in Washington DC, confirmed the receipt of Cycle’s “unsolicited, non-binding indication of interest” and stated it would carefully review and evaluate the proposal.
Tribunal reverses CMA’s £35m fine against four anti-nausea pharmaceutical firms May 28, 2024 Four pharmaceutical companies have successfully appealed and reversed a £35m fine imposed by the competition regulator over anti-nausea tablets
‘New era of growth’: FTSE 100 giant Astrazeneca aims to double revenue May 21, 2024 London-listed Astrazeneca reported revenue of $45.8bn in 2023 and growth of 19 per cent to $12.7bn in the first quarter of 2024.
Haleon posts healthy first quarter update after UK job cuts May 1, 2024 Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.
GSK raises 2024 guidance after strong vaccine sales May 1, 2024 In its first quarter, British company GSK said sales rose 10 per cent to £7.4bn but total operating profit fell 18 per cent to £1.49bn.
Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York April 25, 2024 Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.